Please ensure Javascript is enabled for purposes of website accessibility

Why Invacare Corporation's Shares Rallied 12.1% Today

By Todd Campbell - Apr 28, 2017 at 4:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Invacare may be getting closer to resolving the FDA consent decree that's weighing down its results.

What happened

Shares of Invacare Corporation (IVC -5.06%) climbed 12% today after the company reported that it expects the U.S. Food and Drug Administration (FDA) to initiate an inspection within the next 30 days of two facilities subject to a 2012 consent decree that's hamstrung the company's ability to design and manufacture wheelchairs.

So what

According to an agreement between the company and the FDA approved by the U.S. District Court in 2012, the company is limited in its manufacturing and distribution of wheelchairs and related components at its Taylor Street manufacturing facility in Elyria, Ohio. The decree also limited wheelchair and power-bed design activity at its Elyria, Ohio facility.

A man in a wheelchair outside of a building raises his arms vertically as if to fly.

IMAGE SOURCE: GETTY IMAGES.

Invacare has been working to resolve the FDA concerns regarding those facilities, and today, management reported it had submitted a third-party expert certification report to the FDA confirming the company's substantial compliance with FDA regulatory requirements, as well as the company's own report. Those two reports were necessary before the FDA would agree to inspect the two facilities.

Management expects that the FDA will begin its inspection within the next 30 days in compliance with the consent decree. If that inspection goes smoothly, it will allow the company to return those facilities to full operation.

Now what

The company's financials have taken a hit because of the consent decree and work necessary to address the FDA's concerns, so a restart of the facilities would undeniably be good news.

IVC Revenue (TTM) Chart

IVC Revenue (TTM) data by YCharts.

However, there's no timeline for how long the FDA inspection may last, nor is there any guarantee that the FDA will walk away satisfied from its inspection. The company had taken steps toward winning an FDA green light back in 2015 only to face more questions that required addressing.

Because of the uncertainty in timing and outcome, investors might want to take a more cautious wait-and-see approach to this company's stock rather than rush in to buy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invacare Corporation Stock Quote
Invacare Corporation
IVC
$0.83 (-5.06%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.